Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 1/2012

01-01-2012 | Review

Thrombomodulin and its role in inflammation

Author: Edward M. Conway

Published in: Seminars in Immunopathology | Issue 1/2012

Login to get access

Abstract

The goal is to provide an extensive review of the physiologic role of thrombomodulin (TM) in maintaining vascular homeostasis, with a focus on its anti-inflammatory properties. Data were collected from published research. TM is a transmembrane glycoprotein expressed on the surface of all vascular endothelial cells. Expression of TM is tightly regulated to maintain homeostasis and to ensure a rapid and localized hemostatic and inflammatory response to injury. By virtue of its strategic location, its multidomain structure and complex interactions with thrombin, protein C (PC), thrombin activatable fibrinolysis inhibitor (TAFI), complement components, the Lewis Y antigen, and the cytokine HMGB1, TM exhibits a range of physiologically important anti-inflammatory, anti-coagulant, and anti-fibrinolytic properties. TM is an essential cofactor that impacts on multiple biologic processes. Alterations in expression of TM and its partner proteins may be manifest by inflammatory and thrombotic disorders. Administration of soluble forms of TM holds promise as effective therapies for inflammatory diseases, and infections and malignancies that are complicated by disseminated intravascular coagulation.
Literature
1.
Owen WG, Esmon CT (1981) Functional proerties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 256:5532–5535PubMed
2.
Esmon CT, Owen WG (2004) The discovery of thrombomodulin. J Thromb Haemost 2:209–213PubMed
3.
Ulutin ON, Seegers WH (1962) Autoprothrombin II and autoprothrombin II anticoagulant. Thromb Diath Haemorrh 7(Suppl):256–263PubMed
4.
Esmon CT, Stenflo J, Suttie JW (1976) A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem 251:3052–3056PubMed
5.
Stenflo J (1976) A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem 251:355–363PubMed
6.
Kisiel W, Canfield WM, Ericsson EH, Davie EW (1977) Anticoagulant properties of bovine plasma protein C following activation of thrombin. Biochemistry 16:5824–5831PubMed
7.
Salem HH, Maruyama I, Ishii H, Majerus PW (1984) Isolation and characterization of thrombomodulin from human placenta. J Biol Chem 259:12246–12251PubMed
8.
Maruyama I, Bell C, Majerus P (1985) Thrombomodulin is found on endothelium of arteries, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 101:363–371PubMed
9.
Kawanami O, Jin E, Ghazizadeh M, Fujiwara M, Jiang L, Nagashima M et al (2000) Heterogeneous distribution of thrombomodulin and von Willebrand factor in endothelial cells in the human pulmonary microvessels. J Nippon Med Sch 67:118–125
10.
Raife TJ, Lager DJ, Madison KC, Piette WW, Howard EJ, Sturm MT et al (1994) Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation. J Clin Invest 93:1846–1851PubMed
11.
Conway E, Nowakowski B, Steiner-Mosonyi M (1992) Human neutrophils synthesize thrombomodulin that does not promote thrombin-dependent protein C activation. Blood 80:1254–1263PubMed
12.
Conway E, Nowakowski B (1993) Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. Blood 81:726–733PubMed
13.
McCachren SS, Diggs J, Weinberg JB, Dittman WA (1991) Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood 78:3128–3132PubMed
14.
Soff GA, Jackman RW, Rosenberg RD (1991) Expression of thrombomodulin by smooth muscle cells in culture: different effects of tumor necrosis factor and cyclic adenosine monophosphate on thrombomodulin expression by endothelial cells and smooth muscle cells in culture. Blood 77:515–518PubMed
15.
Boffa M-C, Burke B, Haudenschild C (1987) Preservation of thrombomodulin antigen on vascular and extravascular surfaces. J Histochem Cytochem 35:1267–1276PubMed
16.
Boffa M, Jackman R, Peyri N, Boffa J, George B (1991) Thrombomodulin in the central nervous system. Nouv Rev Fr Hematol 33:423–429PubMed
17.
Maillard C, Berruyer M, Serre CM, Amiral J, Dechavanne M, Delmas PD (1993) Thrombomodulin is synthesized by osteoblasts, stimulated by 1,25-(OH)2D3 and activates protein C at their cell membrane. Endocrinology 133:668–674PubMed
18.
Imada M, Imada S, Iwasaki H, Kume A, Yamaguchi H, Moore E (1987) Fetomodulin: marker surface protein of fetal development which is modulatable by cyclic AMP. Dev Biol 122:483–491PubMed
19.
Imada S, Yamaguchi H, Nagumo M, Katayanagi S, Iwasaki H, Imada M (1990) Identification of fetomodulin, a surface marker protein of fetal development, as thrombomodulin by gene cloning and functional assays. Dev Biol 140:113–122PubMed
20.
Wong V, Hofman FM, Ishii H, Fisher M (1991) Regional distribution of thrombomodulin in human brain. Brain Res 556:1–5PubMed
21.
Tran ND, Wang L, Schreiber SS, Zlokovic B, Fisher M (1998) Measurement of thrombomodulin mRNA expression in brain capillaries by polymerase chain reaction [in process citation]. Thromb Res 91:191–197PubMed
22.
Wang L, Tran N, Kittaka M, Fisher M, Schreiber S, Zlokovic B (1997) Thrombomodulin expression in bovine brain capillaries. Anticoagulant function of the blood–brain barrier, regional differences, and regulatory mechanisms. Arterioscler Thromb Vasc Biol 17:3139–3146PubMed
23.
Jackson MT, Smith MM, Smith SM, Jackson CJ, Xue M, Little CB (2009) Activation of cartilage matrix metalloproteinases by activated protein C. Arthritis Rheum 60:780–791PubMed
24.
Wang L, Bastarache JA, Wickersham N, Fang X, Matthay MA, Ware LB (2007) Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 36:497–503PubMed
25.
Kawamura H, Hiramatsu Y, Watanabe I (1996) Localization of thrombomodulin in a rabbit eye. Curr Eye Res 15:938–942PubMed
26.
Yerkovich ST, Roponen M, Smith ME, McKenna K, Bosco A, Subrata LS, et al (2009) Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141) expression on dendritic cells is associated with a TH2-skewed immune response. J Allergy Clin Immunol 123:209.e4–216.e4.
27.
Isermann B, Hendrickson SB, Hutley K, Wing M, Weiler H (2001) Tissue-restricted expression of thrombomodulin in the placenta rescues thrombomodulin-deficient mice from early lethality and reveals a secondary developmental block. Development 128:827–838PubMed
28.
Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL et al (2003) The thrombomodulin–protein C system is essential for the maintenance of pregnancy. Nat Med 9:331–337PubMed
29.
Boehme MW, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W et al (1996) Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology 87:134–140PubMed
30.
Lohi O, Urban S, Freeman M (2004) Diverse substrate recognition mechanisms for rhomboids: thrombomodulin is cleaved by mammalian rhomboids. Curr Biol 14:236–241PubMed
31.
Yamamoto S, Mizoguchi T, Tamaki T, Ohkuchi M, Kimura S, Aoki N (1993) Urinary thrombomodulin, its isolation and characterization. J Biochem 113:433–440PubMed
32.
Jackman RW, Beeler DL, Fritze L, Soff G, Rosenberg RD (1987) Human thrombomodulin gene is intron depleted: nucleic acid sequences of the cDNA and gene predict protein structure and suggest sites of regulatory control. Proc Natl Acad Sci USA 84:6425–6429PubMed
33.
Wen D, Dittman WA, Ye RD, Deaven LL, Majerus PW, Sadler JE (1987) Human thrombomodulin: complete cDNA sequence and chromosome localization of the gene. Biochemistry 6:2960–2967
34.
Suzuki K, Kusomoto H, Deyashiki Y, Hishioka J, Maruyama I, Zushi M et al (1987) Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 6:1891–1897PubMed
35.
Suzuki K, Deyashiki Y, Nishioka J, Kurachi K, Akira M, Yamamoto S et al (1987) Characterization of a cDNA for human protein C inhibitor. A new member of the plasma serine protease inhibitor superfamily. J Biol Chem 262:611–616PubMed
36.
Villoutreix B, Dahlback B (1998) Molecular model for the C-type lectin domain of human thrombomodulin. J Mol Model 4:310–322
37.
Lu R, Esmon NL, Esmon CT, Johnson AE (1989) The active site of the thrombin–thrombomodulin complex. J Biol Chem 264:12956–12962PubMed
38.
Weisel JW, Nagaswami C, Young TA, Light DR (1996) The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy. J Biol Chem 271:31485–31490PubMed
39.
Hamada H, Ishii H, Sakyo K, Horie S, Nishiki K, Kazama M (1995) The epidermal growth factor-like domain of recombinant human thrombomodulin exhibits mitogenic activity for Swiss 3T3 cells. Blood 86:225–233PubMed
40.
Tohda G, Oida K, Okada Y, Kosaka S, Okada E, Takahashi S et al (1998) Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 18:1861–1869PubMed
41.
Kurosawa S, Stearns DJ, Jackson KW, Esmon CT (1988) A 10-kDa cyanogen bromide fragment from the epidermal growth factor homology domain of rabbit thrombomodulin contains the primary thrombin binding site. J Biol Chem 263:5993–5996PubMed
42.
Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K (1989) The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and anticoagulant activity. J Biol Chem 264:10351–10353PubMed
43.
Suzuki K, Hayashi T, Nishioka J, Kosaka Y, Zushi M, Honda G et al (1989) A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem 264:4872–4876PubMed
44.
Wang W, Nagashima M, Schneider M, Morser J, Nesheim M (2000) Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem 275:22942–22947PubMed
45.
Schenk-Braat EA, Morser J, Rijken DC (2001) Identification of the epidermal growth factor-like domains of thrombomodulin essential for the acceleration of thrombin-mediated inactivation of single-chain urokinase-type plasminogen activator. Eur J Biochem 268:5562–5569PubMed
46.
Bourin MC, Lundgren ÅE, Lindahl U (1990) Isolation and characterization of the glycosaminoglycan component of rabbit thrombomodulin proteoglycan. J Biol Chem 265:15424–15431PubMed
47.
Conway E, Nowakowski B, Steiner-Mosonyi M (1994) Thrombomodulin lacking the cytoplasmic domain efficiently internalizes thrombin via nonclathrin-coated, pit-mediated endocytosis. J Cell Physiol 158:285–298PubMed
48.
Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Weitz JI et al (1999) Structure–function analyses of thrombomodulin by gene-targeting in mice: the cytoplasmic domain is not required for normal fetal development. Blood 93:3442–3450PubMed
49.
Adler M, Seto MH, Nitecki DE, Lin JH, Light DR, Morser J (1995) The structure of a 19-residue fragment from the C-loop of the fourth epidermal growth factor-like domain of thrombomodulin. J Biol Chem 270:23366–23372PubMed
50.
Wood MJ, Sampoli Benitez BA, Komives EA (2000) Solution structure of the smallest cofactor-active fragment of thrombomodulin. Nat Struct Biol 7:200–204PubMed
51.
Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M et al (2000) Structural basis for the anticoagulant activity of the thrombin–thrombomodulin complex [see comments]. Nature 404:518–525PubMed
52.
Koeppe JR, Seitova A, Mather T, Komives EA (2005) Thrombomodulin tightens the thrombin active site loops to promote protein C activation. Biochemistry 44:14784–14791PubMed
53.
Tsiang M, Lentz SR, Sadler JE (1992) Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 267:6164–6170PubMed
54.
Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L (1997) Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78:386–391PubMed
55.
Wu C, Kim PY, Manuel R, Seto M, Whitlow M, Nagashima M, Morser J, Gils A, Declerck P, Nesheim ME (2009) The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. J Biol Chem 284:7059–7067
56.
Light DR, Glaser CB, Betts M, Blasko E, Campbell E, Clarke JH et al (1999) The interaction of thrombomodulin with Ca2+. Eur J Biochem 262:522–533PubMed
57.
Adams TE, Huntington JA (2006) Thrombin–cofactor interactions: structural insights into regulatory mechanisms. Arterioscler Thromb Vasc Biol 26:1738–1745PubMed
58.
Grinnell BW, Berg DT (1996) Surface thrombomodulin modulates thrombin receptor responses on vascular smooth muscle cells. Am J Physiol 270:H603–H609PubMed
59.
Lafay M, Laguna R, Le Bonniec BF, Lasne D, Aiach M, Rendu F (1998) Thrombomodulin modulates the mitogenic response to thrombin of human umbilical vein endothelial cells. Thromb Haemost 79:848–852PubMed
60.
Esmon CT, Esmon NL, Harris KW (1982) Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 257:7944–7947PubMed
61.
Esmon NL, Carroll RC, Esmon CT (1983) Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 258:12238–12242PubMed
62.
Ye J, Esmon C, Johnson A (1993) The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J Biol Chem 268:2373–2379PubMed
63.
Stenflo J, Fernlund P (1982) Amino acid sequence of the heavy chain of bovine protein C. J Biol Chem 257:12180–12190PubMed
64.
Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 93:10212–10216PubMed
65.
Fukudome K, Ye X, Tsuneyoshi N, Tokunaga O, Sugawara K, Mizokami H et al (1998) Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor. J Exp Med 187:1029–1035PubMed
66.
Laszik Z, Mitro A, Taylor FB Jr, Ferrell G, Esmon CT (1997) Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 96:3633–3640PubMed
67.
Fukudome K, Esmon C (1995) Molecular cloning and expression of murine and bovine endothelial cell protein C/activated protein C receptor (EPCR). J Biol Chem 270:5571–5577PubMed
68.
Dahlback B, Villoutreix BO (2005) Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure–function relationships and molecular recognition. Arterioscler Thromb Vasc Biol 25:1311–1320PubMed
69.
Slungaard A, Fernandez JA, Griffin JH, Key NS, Long JR, Piegors DJ et al (2003) Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood 102:146–151PubMed
70.
Slungaard A (2005) Platelet factor 4: a chemokine enigma. Int J Biochem Cell Biol 37:1162–1167PubMed
71.
Cooper ST, Rezaie AR, Esmon CT, Church FC (2002) Inhibition of a thrombin anion-binding exosite-2 mutant by the glycosaminoglycan-dependent serpins protein C inhibitor and heparin cofactor II. Thromb Res 107:67–73PubMed
72.
Yang L, Manithody C, Walston TD, Cooper ST, Rezaie AR (2003) Thrombomodulin enhances the reactivity of thrombin with protein C inhibitor by providing both a binding site for the serpin and allosterically modulating the activity of thrombin. J Biol Chem 278:37465–37470PubMed
73.
Preissner KT, Delvos U, Muller-Berghaus G (1987) Binding of thrombin to thrombomodulin accelerates inhibition of the enzyme by antithrombin III. Evidence for a heparin-independent mechanism. Biochemistry 26:2521–2528PubMed
74.
Riewald M, Petrovan RJ, Donner A, Ruf W (2003) Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. J Endotoxin Res 9:317–321PubMed
75.
Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED et al (2003) Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 9:338–342PubMed
76.
Krupiczojc MA, Scotton CJ, Chambers RC (2008) Coagulation signalling following tissue injury: focus on the role of factor Xa. Int J Biochem Cell Biol 40:1228–1237PubMed
77.
Levi M (2010) The coagulant response in sepsis and inflammation. Hämostaseologie 30(10–12):14–16
78.
Bajzar L, Manuel R, Nesheim M (1995) Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270:14477–14484PubMed
79.
Dai L, Mitchell M, Savidge G, Alhaq A (2004) The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis. J Thromb Haemost 2:2200–2204PubMed
80.
Nagashima M, Yin ZF, Broze GJ Jr, Morser J (2002) Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice. Front Biosci 7:d556–d568PubMed
81.
Vercauteren E, Emmerechts J, Peeters M, Hoylaerts MF, Declerck PJ, Gils A (2011) Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Blood 117:4615–4622
82.
Campbell WD, Lazoura E, Okada N, Okada H (2002) Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 46:131–134PubMed
83.
Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, et al (2003) Thrombin activatable fibrinolysis inhibitor: a potential regulator of vascular inflammation. J Biol Chem 278:51059–51067
84.
Morser J, Gabazza EC, Myles T, Leung LL (2010) What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse? J Thromb Haemost 8:868–876PubMed
85.
Kokame K, Zheng X, Sadler J (1998) Activation of thrombin-activatable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 273:12135–12139PubMed
86.
Glaser C, Morser J, Clarke J, Blasko E, McLean K, Kuhn I et al (1992) Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest 90:2565–2573PubMed
87.
Wood MJ, Becvar LA, Prieto JH, Melacini G, Komives EA (2003) NMR structures reveal how oxidation inactivates thrombomodulin. Biochemistry 42:11932–11942PubMed
88.
Wood MJ, Helena Prieto J, Komives EA (2005) Structural and functional consequences of methionine oxidation in thrombomodulin. Biochim Biophys Acta 1703:141–147PubMed
89.
Adams GN, Larusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH et al (2011) Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 117:3929–3937PubMed
90.
Mosnier LO (2011) Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. J Biol Chem 286:502–510PubMed
91.
DeMunk G, Groeneveld E, Rijken DC (1991) Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (Pro-urokinase) by thrombomodulin. J Clin Invest 88:1680–1684
92.
Molinari A, Giorgetti C, Lansen J, Vaghi F, Orsini G, Faioni E et al (1992) Thrombomodulin is a cofactor for thrombin degradation of recombinant single-chain urokinase plasminogen activator “in vitro” and in a perfused rabbit heart model. Thromb Haemost 67:226–232PubMed
93.
Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B et al (2010) Molecular intercommunication between the complement and coagulation systems. J Immunol 185:5628–5636PubMed
94.
Fu X, Parks WC, Heinecke JW (2008) Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol 19:2–13PubMed
95.
Moore KL, Esmon CT, Esmon NL (1989) Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 73:159–165PubMed
96.
Maruyama I, Majerus PW (1985) The turnover of thrombin–thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. J Biol Chem 260:15432–15438PubMed
97.
Beretz A, Freysinnet J-M, Gauchy J, Schmitt DA, Klein-Soyer C, Edgell C-JS et al (1989) Stability of the thrombin-thrombomodulin complex on the surface of endothelial cells from human saphenous vein or from the cell line EA.hy 926. Biochem J 259:35–40PubMed
98.
Brisson C, Archipoff G, Harrmann M-L, Hanau D, Beretz A, Freyssinet J-M et al (1993) Antibodies to thrombomodulin induce receptor-mediated endocytosis in human saphenous vein endothelial cells. Thromb Haemost 68:737–743
99.
Hirokawa K, Aoki N (1991) Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro. J Cell Physiol 147:157–165PubMed
100.
Hirokawa K, Aoki N (1990) Up-regulation of thrombomodulin in human umbilical vein endothelial cells in vitro. J Biochem (Tokyo) 108:839–845
101.
Maruyama I, Majerus P (1987) Protein C inhibits endocytosis of thrombin-thrombomodulin complexes in A549 lung cancer cells and human umbilical vein endothelial cells. Blood 69:1481–1484PubMed
102.
Conway E, Boffa M, Nowakowski B, Steiner-Mosonyi M (1992) An ultrastructural study of thrombomodulin endocytosis: internalization occurs via clathrin-coated and non-coated pits. J Cell Physiol 151:604–612PubMed
103.
Tazawa T, Hirosawa S, Suzuki K, Hirokawa K, Aoki N (1993) Functional characterization of the 5′-regulatory region of the human thrombomodulin gene. J Biochem (Tokyo) 113:600–606
104.
Yu K, Morioka H, Fritze L, Beeler D, Jackman R, Rosenberg R (1992) Transcriptional regulation of the thrombomodulin gene. J Biol Chem 267:23237–23247PubMed
105.
Niforas P, Sanderson G, Bird C, Bird P (1993) Characterization of the mouse thrombomodulin gene and functional analysis of the 5′ flanking region in F9 teratocarcinoma cells. Biochim Biophys Acta 1173:179–188PubMed
106.
Malek AM, Jackman R, Rosenberg RD, Izumo S (1994) Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res 74:852–860PubMed
107.
Ohji T, Urano H, Shirahata A, Yamagishi M, Higashi K, Gotoh S et al (1995) Transforming growth factor beta1 and beta2 induce down-modulation of thrombomodulin in human umbilical vein endothelial cells. Thromb Haemost 73:812–818PubMed
108.
Ishii H, Tezuka T, Ishikawa H, Takada K, Oida K, Horie S (2003) Oxidized phospholipids in oxidized low-density lipoprotein down-regulate thrombomodulin transcription in vascular endothelial cells through a decrease in the binding of RARbeta–RXRalpha heterodimers and Sp1 and Sp3 to their binding sequences in the TM promoter. Blood 101:4765–4774PubMed
109.
Rong Y, Zhang M, Zhang L, Wang XL, Shen YH (2010) JNK-ATF-2 inhibits thrombomodulin (TM) expression by recruiting histone deacetylase4 (HDAC4) and forming a transcriptional repression complex in the TM promoter. FEBS Lett 584:852–858PubMed
110.
Sandusky G, Berg DT, Richardson MA, Myers L, Grinnell BW (2002) Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads. J Biol Chem 277:49815–49819PubMed
111.
Nan B, Yang H, Yan S, Lin PH, Lumsden AB, Yao Q et al (2005) C-reactive protein decreases expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Surgery 138:212–222PubMed
112.
Grey ST, Csizmadia V, Hancock WW (1998) Differential effect of tumor necrosis factor-alpha on thrombomodulin gene expression by human monocytoid (THP-1) cell versus endothelial cells [in process citation]. Int J Hematol 67:53–62PubMed
113.
Kim HK, Kim JE, Chung J, Kim YT, Kang SH, Han KS et al (2007) Lipopolysaccharide down-regulates the thrombomodulin expression of peripheral blood monocytes: effect of serum on thrombomodulin expression in the THP-1 monocytic cell line. Blood Coagul Fibrinol 18:157–164
114.
Conway EM, Rosenberg RD (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 8:5588–5592PubMed
115.
Starr ME, Ueda J, Takahashi H, Weiler H, Esmon CT, Evers BM et al (2010) Age-dependent vulnerability to endotoxemia is associated with reduction of anticoagulant factors activated protein C and thrombomodulin. Blood 115:4886–4893PubMed
116.
Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K et al (2005) Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood 105:3910–3917PubMed
117.
Baeuerle PA (1998) IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 95:729–731PubMed
118.
Hamaguchi E, Takamura T, Shimizu A, Nagai Y (2003) Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther 307:987–994PubMed
119.
Parry GC, Mackman N (1995) Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 15:612–621PubMed
120.
Conway EM, Carmeliet P (2004) The diversity of endothelial cells: a challenge for therapeutic angiogenesis. Genome Biol 5:207PubMed
121.
Welch W (1993) Heat shock proteins functioning as molecular chaperones: their roles in normal and stressed cells. Phil Trans R Soc Lond 339:327–333
122.
Morimoto R (1993) Cells in stress: transcriptional activation of heat shock genes. Science 259:1409–1410.
123.
Udelsman R, Blake M, Stagg C, Li D, Putney D, Holbrook N (1993) Vascular heat shock protein expression in response to stress. J Clin Invest 91:465–473PubMed
124.
Bielecka-Dabrowa A, Barylski M, Mikhailidis DP, Rysz J, Banach M (2009) HSP 70 and atherosclerosis—protector or activator? Expert Opin Ther Targets 13:307–317PubMed
125.
Conway E, Liu L, Nowakowski B, Steiner-Mosonyi M, Jackman R (1994) Heat shock of vascular endothelial cells induces an upregulatory transcriptional response of the thrombomodulin gene that is delayed in onset and does not attenuate. J Biol Chem 269:22804–22810PubMed
126.
Drake T, Cheng J, Chang A, Taylor F (1993) Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Path 142:1458–1470PubMed
127.
Nawroth P, Stern D (1986) Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163:740–745PubMed
128.
Laszik Z, Carson CW, Nadasdy T, Johnson LD, Lerner MR, Brackett DJ et al (1994) Lack of suppressed renal thrombomodulin expression in a septic rat model with glomerular thrombotic microangiopathy. Lab Invest 70:862–867PubMed
129.
Wong HR, Ryan M, Wispe JR (1997) Stress response decreases NF-kappaB nuclear translocation and increases I-kappaBalpha expression in A549 cells. J Clin Invest 99:2423–2428PubMed
130.
Calnek DS, Grinnell BW (1998) Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor. Exp Cell Res 238:294–298PubMed
131.
Dittman WA, Kumada T, Majerus PW (1989) Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin. Proc Natl Acad Sci USA 86:7179–7182PubMed
132.
Maruyama I, Soejima Y, Osame M, Ito T, Ogawa K, Yamamoto S et al (1991) Increased expression of thrombomodulin on the cultured human umbilical vein endothelial cells and mouse hemangioma cells by cyclic AMP. Thromb Res 61:301–310PubMed
133.
Weiler GH, Yu K, Soff G, Gudas LJ, Rosenberg RD (1992) Thrombomodulin gene regulation by cAMP and retinoic acid in F9 embryonal carcinoma cells. Proc Natl Acad Sci USA 89:2155–2159
134.
Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D et al (2003) Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinol 14:575–585
135.
Rees DA, Giles P, Lewis MD, Ham J (2010) Adenosine regulates thrombomodulin and endothelial protein C receptor expression in folliculostellate cells of the pituitary gland. Purinergic Signal 6:19–29PubMed
136.
Lentz SR, Sadler JE (1991) Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88:1906–1914PubMed
137.
Abe H, Okajima K, Okabe H, Takatsuki K, Binder BR (1994) Granulocyte proteases and hydrogen peroxide synergistically inactivate thrombomodulin of endothelial cells in vitro. J Lab Clin Med 123:874–881PubMed
138.
Redl H, Schlag G, Schiesser A, Davies J (1995) Thrombomodulin release in baboon sepsis: its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor. J Infect Dis 171:1522–1527PubMed
139.
Inomata M, Ishihara Y, Matsuyama T, Imamura T, Maruyama I, Noguchi T et al (2009) Degradation of vascular endothelial thrombomodulin by arginine- and lysine-specific cysteine proteases from Porphyromonas gingivalis. J Periodontol 80:1511–1517PubMed
140.
Glusa E (1992) Vascular effects of thrombin. Sem Thromb Hemost 18:296–304
141.
Bizios R, Lai L, Fenton JW 2nd, Malik AB (1986) Thrombin-induced chemotaxis and aggregation of neutrophils. J Cell Physiol 128:485–490PubMed
142.
Kudhal K, Fisker S, Sonne O (1991) A thrombin receptor in resident rat peritoneal macrophages. Exp Cell Res 193:45–53
143.
Naldini A, Bernini C, Pucci A, Carraro F (2005) Thrombin-mediated IL-10 up-regulation involves protease-activated receptor (PAR)-1 expression in human mononuclear leukocytes. J Leukoc Biol 78:736–744PubMed
144.
Naldini A, Carney DH, Bocci V, Klimpel KD, Asuncion M, Soares LE et al (1993) Thrombin enhances T cell proliferative responses and cytokine production. Cell Immunol 147:367–377PubMed
145.
Naldini A, Carney DH, Pucci A, Carraro F (2002) Human alpha-thrombin stimulates proliferation of interferon-gamma differentiated, growth-arrested U937 cells, overcoming differentiation-related changes in expression of p21CIP1/WAF1 and cyclin D1. J Cell Physiol 191:290–297PubMed
146.
Naldini A, Carney DH, Pucci A, Pasquali A, Carraro F (2000) Thrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1. Gen Pharmacol 35:255–259PubMed
147.
Naldini A, Pucci A, Carney DH, Fanetti G, Carraro F (2002) Thrombin enhancement of interleukin-1 expression in mononuclear cells: involvement of proteinase-activated receptor-1. Cytokine 20:191–199PubMed
148.
Chen L, Teng N, Buchanan J (1976) Mitogenicity of thrombin and surface alterations on mouse splenocytes. Exp Cell Res 101:41–46PubMed
149.
Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD (1986) Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci USA 83:976–980PubMed
150.
Bar-Shavit R, Hruska K, Kahn A, Wilner G (1986) Hormone-like activity of human thrombin. Ann NY Acad Sci 485:335–348PubMed
151.
Tatakis D, Dolce C, Dziak R (1989) Thrombin’s effects on osteoblastic cells. I. Cytosolic calcium and phosphoinositides. Biochem Biophys Res Commun 164:119–127PubMed
152.
Furmaniak-Kazmierczak E, Cooke T, Manuel R, Scudamore A, Hoogendorn H, Giles A et al (1994) Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage. J Clin Invest 94:472–480PubMed
153.
Tang H, Low B, Rutherford SA, Hao Q (2005) Thrombin induces endocytosis of endoglin and type-II TGF-beta receptor and down-regulation of TGF-beta signaling in endothelial cells. Blood 105:1977–1985PubMed
154.
Vu TK, Hung DT, Wheaton VI, Coughlin SR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057–1068PubMed
155.
Woolkalis M, DeMelfi TJ, Blanchard N, Hoxie J, Brass L (1995) Regulation of thrombin receptors on human umbilical vein endothelial cells. J Biol Chem 270:9868–9875.
156.
Minami T, Sugiyama A, Wu SQ, Abid R, Kodama T, Aird WC (2004) Thrombin and phenotypic modulation of the endothelium. Arterioscler Thromb Vasc Biol 24:41–53PubMed
157.
Coughlin SR, Camerer E (2003) PARticipation in inflammation. J Clin Invest 111:25–27PubMed
158.
Trejo J (2003) Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther 307:437–442PubMed
159.
Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N et al (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26:1–43PubMed
160.
Bhattacharya A, Cohen ML (2000) Vascular contraction and relaxation to thrombin and trypsin: thrombomodulin preferentially attenuates thrombin-induced contraction. J Pharmacol Exp Ther 295:284–290PubMed
161.
Olivot JM, Estebanell E, Lafay M, Brohard B, Aiach M, Rendu F (2001) Thrombomodulin prolongs thrombin-induced extracellular signal-regulated kinase phosphorylation and nuclear retention in endothelial cells. Circ Res 88:681–687PubMed
162.
Dufilho M, Millanvoye-Van Brussel E, Topal G, Walch L, Brunet A, Rendu F (2005) Endothelial thrombomodulin induces Ca2+ signals and no synthesis through epidermal growth factor receptor kinase and calmodulin kinase II. J Biol Chem 280:35999–36006
163.
Taylor FJ, Chang A, Esmon CT, Hinshaw LB (1991) Baboon model of Escherichia coli sepsis: description of its four stages and the role of tumor necrosis factor, tissue factors, and the protein C system in septic shock. Curr Stud Hematol Blood Transfus 58:8–14PubMed
164.
Taylor F, Stearns-Kurosawa D, Kurosawa S, Ferrell G, Chang A, Laszik Z et al (2000) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95(5):1680–1686PubMed
165.
Hancock WW, Sayegh MH, Sablinski T, Kut JP, Kupiec-Weglinski JW, Milford EL (1992) Blocking of mononuclear cell accumulation, cytokine production, and endothelial activation within rat cardiac allografts by CD4 monoclonal antibody therapy. Transplantation 53:1276–1280PubMed
166.
Hirose K, Okajima K, Taoka Y, Uchiba M, Tagami H, Nakano K et al (2000) Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 232:272–280PubMed
167.
Mizutani A, Okajima K, Uchiba M, Noguchi T (2000) Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 95:3781–3787PubMed
168.
Levi M, Choi G, Schoots I, Schultz M, Van Der Poll T (2004) Beyond sepsis: activated protein C and ischemia–reperfusion injury. Crit Care Med 32:S309–312PubMed
169.
Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW (1994) Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 153:3664–3672PubMed
170.
Brueckmann M, Hoffmann U, Dvortsak E, Lang S, Kaden JJ, Borggrefe M et al (2004) Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis. Inflamm Res 53:528–533PubMed
171.
Levi M, Dorffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T et al (2003) Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 101:4823–4827PubMed
172.
Ganopolsky JG, Castellino FJ (2004) A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol 165:1433–1446PubMed
173.
Weiler-Guettler H, Christie P, Beeler D, Healy A, Hancock W, Rayburn H et al (1998) A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 101:1–9
174.
Weiler H, Lindner V, Kerlin B, Isermann B, Hendrickson S, Cooley B et al (2001) Characterization of a mouse model for thrombomodulin deficiency. Arterioscler Thromb Vasc Biol 21:1531–1537PubMed
175.
Rijneveld AW, Weijer S, Florquin S, Esmon CT, Meijers JC, Speelman P, et al (2003) Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 103:1702–1709
176.
Dahlback B (2003) The discovery of activated protein C resistance. J Thromb Haemost 1:3–9PubMed
177.
Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67PubMed
178.
Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR et al (2003) Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 102:3085–3092PubMed
179.
Weiler H, Kerlin B, Lytle MC (2004) Factor V Leiden polymorphism modifies sepsis outcome: evidence from animal studies. Crit Care Med 32:S233–238PubMed
180.
Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NL et al (2002) The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 277:24851–24854PubMed
181.
Esmon CT (2004) Structure and functions of the endothelial cell protein C receptor. Crit Care Med 32:S298–S301PubMed
182.
Kurosawa S, Stearns-Kurosawa DJ, Hidari N, Esmon CT (1997) Identification of functional endothelial protein C receptor in human plasma. J Clin Invest 100:411–418PubMed
183.
Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D’Angelo A, Della Valle P, Esmon CT (1998) Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 91:725–727PubMed
184.
Xu J, Qu D, Esmon NL, Esmon CT (2000) Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem 275:6038–6044PubMed
185.
Kurosawa S, Esmon CT, Stearns-Kurosawa DJ (2000) The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 165:4697–4703PubMed
186.
Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296:1880–1882.
187.
Feistritzer C, Riewald M (2005) Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105:3178–3184PubMed
188.
Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y et al (2002) Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 61:490–501PubMed
189.
Koyama T, Parkinson JF, Aoki N, Bang NU, Müller BG, Preissner KT (1991) Relationship between post-translational glycosylation and anticoagulant function of secretable recombinant mutants of human thrombomodulin. Br J Haematol 78:515–522PubMed
190.
Bourin MC, Lindahl U (1990) Functional role of the polysaccharide component of rabbit thrombomodulin proteoglycan. Effects on inactivation of thrombin by antithrombin, cleavage of fibrinogen by thrombin and thrombin-catalysed activation of Factor V. Biochem J 270:419–425PubMed
191.
Rabhi-Sabile S, Steiner-Mosonyi M, Pollefeyt S, Collen D, Pouvelle B, Gysin J et al (1999) Plasmodium falciparum-infected erythrocytes: a mutational analysis of cytoadherence via murine thrombomodulin. Thromb Haemost 81:815–821PubMed
192.
Warrell D, Molyneux M, Beales P (1990) Severe and complicated malaria. Trans R Soc Trop Med Hyg 84:1–65
193.
Rogerson SJ (2003) Sequestration: causes and consequences. Redox Rep 8:295–299PubMed
194.
Gitau EN, Newton CR (2005) Review article: blood–brain barrier in falciparum malaria. Trop Med Int Health 10:285–292PubMed
195.
Fried M, Duffy P (1996) Adherence of Plasmodium falciparum to chondroitin sulfate A in the human placenta. Science 272:1502–1504.
196.
Fried M, Duffy P (1998) Maternal malaria and parasite adhesion. J Mol Med 76:162–171PubMed
197.
Pouvelle B, Meyer P, Robert C, Bardel L, Gysin J (1997) Chondroitin-4-sulfate impairs in vitro and in vivo cytoadherence of Plasmodium falciparum infected erythrocytes. Mol Med 3:508–518PubMed
198.
Beeson JG, Chai W, Rogerson SJ, Lawson AM, Brown GV (1998) Inhibition of binding of malaria-infected erythrocytes by a tetradecasaccharide fraction from chondroitin sulfate A. Infect Immun 66:3397–3402PubMed
199.
Edano T, Kumai N, Mizoguchi T, Ohkuchi M (1998) The glycosylation sites and structural characteristics of oligosaccharides on recombinant human thrombomodulin. Int J Biochem Cell Biol 30:77–88PubMed
200.
Lin J-H, McLean K, Morser J, Young T, Wydro R, Andrews W et al (1994) Modulation of glycosaminoglycan addition in naturally expressed and recombinant human thrombomodulin. J Biol Chem 269:25021–25030PubMed
201.
Gerlitz B, Hassell T, Vlahos CJ, Parkinson JF, Bang NU, Grinnell BW (1993) Identification of the predominant glycosaminoglycan-attachment site in soluble recombinant human thrombomodulin: potential regulation of functionality by glycosyltransferase competition for serine474. Biochem J 295:131–140PubMed
202.
Pouvelle B, Fusai T, Gysin J (1998) Revue generale. Plasmodium falciparum et chondroitin-4-sulfate: Le nouveau couple cle de al sequestration. Med Trop 58:187–198.
203.
Pruna A, Peyri N, Berard M, Boffa M-C (1997) Thrombomodulin is synthesized by human mesangial cells. Kidney Int 51:687–693PubMed
204.
Salanti A, Dahlback M, Turner L, Nielsen MA, Barfod L, Magistrado P et al (2004) Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 200:1197–1203PubMed
205.
Dodd RB, Drickamer K (2001) Lectin-like proteins in model organisms: implications for evolution of carbohydrate-binding activity. Glycobiology 11:71R–79RPubMed
206.
Vasta GR, Quesenberry M, Ahmed H, O’Leary N (1999) C-type lectins and galectins mediate innate and adaptive immune functions: their roles in the complement activation pathway. Dev Comp Immunol 23:401–420PubMed
207.
Drickamer K (1988) Two distinct classes of carbohydrate-recognition domains in animal lectins. J Biol Chem 263:9557–9560PubMed
208.
Sim RB, Tsiftsoglou SA (2004) Proteases of the complement system. Biochem Soc Trans 32:21–27PubMed
209.
Petersen T (1988) The amino-terminal domain of thrombomodulin and pancreatic stone protein are homologous with lectins. FEBS Lett 231:51–53PubMed
210.
Patthy L (1988) Detecting distant homologies of mosaic proteins. Analysis of the sequences of thrombomodulin, thrombospondin, complement components C9, C8 alpha and C8 beta, vitronectin and plasma cell membrane glycoprotein PC-1. J Mol Biol 202:689–696PubMed
211.
Opavsky R, Haviernik P, Jurkovicova D, Garin MT, Copeland NG, Gilbert DJ et al (2001) Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J Biol Chem 276:38795–38807PubMed
212.
MacFadyen JR, Haworth O, Roberston D, Hardie D, Webster MT, Morris HR et al (2005) Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett 579:2569–2575PubMed
213.
McGreal E, Gasque P (2002) Structure–function studies of the receptors for complement C1q. Biochem Soc Trans 30:1010–1014PubMed
214.
Greenlee MC, Sullivan SA, Bohlson SS (2008) CD93 and related family members: their role in innate immunity. Curr Drug Targets 9:130–138PubMed
215.
Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A et al (2002) The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 196:565–577PubMed
216.
Geudens N, Van de Wouwer M, Vanaudenaerde BM, Vos R, Van De Wauwer C, Verleden GM et al (2008) The lectin-like domain of thrombomodulin protects against ischaemia–reperfusion lung injury. Eur Respir J 32:862–870PubMed
217.
Van de Wouwer M, Plaisance S, DeVries A, Waelkens E, Collen D, Persson J et al (2006) The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 4:1813–1824PubMed
218.
Abeyama K, Stern DM, Ito Y, Kawahara KI, Yoshimoto Y, Tanaka M, et al (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115:1267–1274
219.
Alleva LM, Yang H, Tracey KJ, Clark IA (2005) High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria. Trans R Soc Trop Med Hyg 99:171–174PubMed
220.
Chen G, Li J, Qiang X, Czura CJ, Ochani M, Ochani K et al (2005) Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46:623–627PubMed
221.
Yang H, Wang H, Czura CJ, Tracey KJ (2005) The cytokine activity of HMGB1. J Leukoc Biol 78:1–8PubMed
222.
Mun-Bryce S, Rosenberg G (1998) Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 18:1163–1172PubMed
223.
Schmidt AM, Yan SD, Yan SF, Stern DM (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498:99–111PubMed
224.
Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342PubMed
225.
Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H et al (2008) Proteolytic cleavage of high mobility group box 1 protein by thrombin–thrombomodulin complexes. Arterioscler Thromb Vasc Biol 28:1825–1830PubMed
226.
Esmon C (2005) Do-all receptor takes on coagulation, inflammation. Nat Med 11:475–477PubMed
227.
Huang HC, Shi GY, Jiang SJ, Shi CS, Wu CM, Yang HY, et al (2003) Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. J Biol Chem 278:46750–46759
228.
Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY et al (2008) Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 112:3661–3670PubMed
229.
Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G et al (2009) Thrombomodulin mutations in atypical hemolytic–uremic syndrome. New Engl J Med 361:345–357PubMed
230.
Busso N, Morard C, Salvi R, Peclat V, So A (2003) Role of the tissue factor pathway in synovial inflammation. Arthritis Rheum 48:651–659PubMed
231.
Nakano S, Ikata T, Kinoshita I, Kanematsu J, Yasuoka S (1999) Characteristics of the protease activity in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Exp Rheumatol 17:161–170PubMed
232.
Yang YH, Hall P, Little CB, Fosang AJ, Milenkovski G, Santos L et al (2005) Reduction of arthritis severity in protease-activated receptor-deficient mice. Arthritis Rheum 52:1325–1332PubMed
233.
Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T (2005) The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 166:783–792PubMed
234.
Judex MO, Mueller BM (2005) Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. Am J Pathol 166:645–647PubMed
235.
So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Peclat V, Gerster JC et al (2003) Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 1:2510–2515PubMed
236.
Pekovich SR, Bock PE, Hoover RL (2001) Thrombin–thrombomodulin activation of protein C facilitates the activation of progelatinase A. FEBS Lett 494:129–132PubMed
237.
Buisson-Legendre N, Smith S, March L, Jackson C (2004) Elevation of activated protein C in synovial joints in rheumatoid arthritis and its correlation with matrix metalloproteinase 2. Arthritis Rheum 50:2151–2156PubMed
238.
Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT (2001) Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 159:797–802PubMed
239.
Mathew M, Tay E, Cusi K (2010) Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects. Cardiovasc Diabetol 9:9PubMed
240.
Soskic SS, Dobutovic BD, Sudar EM, Obradovic MM, Nikolic DM, Zaric BL, et al (2011) The peroxisome proliferator-activated receptors and atherosclerosis. Angiology [Epub ahead of print]
241.
Mangan S, Clancy P, Golledge J (2008) Modulation of endothelial cell thrombomodulin by PPAR ligands—variation according to environment. Thromb Res 121:827–834PubMed
242.
Reriani MK, Dunlay SM, Gupta B, West CP, Rihal CS, Lerman LO, et al. Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil. 2011.
243.
Lin SJ, Hsieh FY, Chen YH, Lin CC, Kuan II, Wang SH et al (2009) Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFalpha-treated human aortic endothelial cells. Histol Histopathol 24:1147–1159PubMed
244.
Rossi J, Rouleau L, Tardif JC, Leask RL (2010) Effect of simvastatin on Kruppel-like factor2, endothelial nitric oxide synthase and thrombomodulin expression in endothelial cells under shear stress. Life Sci 87:92–99PubMed
245.
Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H et al (2003) Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 23:512–517PubMed
246.
Manthey HD, Thomas AC, Shiels IA, Zernecke A, Woodruff TM, Rolfe B, et al (2011) Complement C5a inhibition reduces atherosclerosis in ApoE−/− mice. FASEB J 25:2447–2455
247.
Speidl WS, Kastl SP, Huber K, Wojta J (2011) Complement in atherosclerosis: friend or foe? J Thromb Haemost 9:428–440PubMed
248.
Yamaji K, Wang Y, Liu Y, Abeyama K, Hashiguchi T, Uchimura T et al (2005) Activated protein C, a natural anticoagulant protein, has antioxidant properties and inhibits lipid peroxidation and advanced glycation end products formation. Thromb Res 115:319–325PubMed
249.
Zorio E, Navarro S, Medina P, Estelles A, Osa A, Rueda J et al (2006) Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions. J Thromb Haemost 4:1530–1536PubMed
250.
Boffa MC, Karmochkine M (1998) Thrombomodulin: an overview and potential implications in vascular disorders. Lupus 7:S120–125PubMed
251.
Lin SM, Wang YM, Lin HC, Lee KY, Huang CD, Liu CY et al (2008) Serum thrombomodulin level relates to the clinical course of disseminated intravascular coagulation, multiorgan dysfunction syndrome, and mortality in patients with sepsis. Crit Care Med 36:683–689PubMed
252.
Matondo Maya DW, Mewono L, Nkoma AM, Issifou S, Mavoungou E (2008) Markers of vascular endothelial cell damage and P. falciparum malaria: association between levels of both sE-selectin and thrombomodulin, and cytokines, hemoglobin and clinical presentation. Eur Cytokine Netw 19:123–130PubMed
253.
Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H et al (1999) Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case–cohort study. Lancet 353:1729–1734PubMed
254.
Wu KK (2003) Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol 14:373–375PubMed
255.
Wu KK, Aleksic N, Ballantyne CM, Ahn C, Juneja H, Boerwinkle E (2003) Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation 107:1729–1732PubMed
256.
Ohlin A-K, Marlar R (1995) The first mutation identified in the thrombomodulin gene in a 45 year old man presenting with thromboembolic disease. Blood 85:330–336PubMed
257.
Kunz G, Ohlin AK, Adami A, Zoller B, Svensson P, Lane DA (2002) Naturally occurring mutations in the thrombomodulin gene leading to impaired expression and function. Blood 99:3646–3653PubMed
258.
Konstantoulas CJ, Cooper J, Warnock G, Miller GJ, Humphries SE, Ireland H (2004) A combination of two common thrombomodulin gene variants (−1208–1209TTdelTT and A455V) influence risk of coronary heart disease: a prospective study in men. Atherosclerosis 177:97–104PubMed
259.
Doggen CJ, Kunz G, Rosendaal FR, Lane DA, Vos HL, Stubbs PJ et al (1998) A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost 80:743–748PubMed
260.
Waugh JM, Yuksel E, Li J, Kuo MD, Kattash M, Saxena R et al (1999) Local overexpression of thrombomodulin for in vivo prevention of arterial thrombosis in a rabbit model. Circ Res 84:84–92PubMed
261.
Mohri M, Oka M, Aoki Y, Gonda Y, Hirata S, Gomi K et al (1994) Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats. Am J Hematol 45:298–303PubMed
262.
Gonda Y, Hirata S, Saitoh K, Aoki Y, Mohri M, Gomi K et al (1993) Antithrombotic effect of recombinant human soluble thrombomodulin on endotoxin-induced disseminated intravascular coagulation in rats. Thromb Res 71:325–335PubMed
263.
Uchiba M, Okajima K, Murakami K, Nawa K, Okabe H, Takatsuki K (1995) Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 74:1265–1270PubMed
264.
Iba T, Nakarai E, Takayama T, Nakajima K, Sasaoka T, Ohno Y (2009) Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care 13:R203.
265.
Taoka Y, Okajima K, Uchiba M, Johno M (2000) Neuroprotection by recombinant thrombomodulin. Thromb Haemost 83:462–468PubMed
266.
Kaneko H, Joubara N, Yoshino M, Yamazaki K, Mitumaru A, Miki Y et al (2000) Protective effect of human urinary thrombomodulin on ischemia–reperfusion injury in the canine liver. Eur Surg Res 32:87–93PubMed
267.
Ozaki T, Anas C, Maruyama S, Yamamoto T, Yasuda K, Morita Y et al (2008) Intrarenal administration of recombinant human soluble thrombomodulin ameliorates ischaemic acute renal failure. Nephrol Dial Transplant 23:110–119PubMed
268.
Sharfuddin AA, Sandoval RM, Berg DT, McDougal GE, Campos SB, Phillips CL et al (2009) Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 20:524–534PubMed
269.
Hagiwara S, Iwasaka H, Goto K, Ochi Y, Mizunaga S, Saikawa T, et al (2010) Recombinant thrombomodulin prevents heat stroke by inhibition of high mobility group box 1 protein in sera of rats. Shock 34:402–406
270.
Sperling C, Salchert K, Streller U, Werner C (2004) Covalently immobilized thrombomodulin inhibits coagulation and complement activation of artificial surfaces in vitro. Biomaterials 25:5101–5113PubMed
271.
Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohri M et al (2004) Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2:1745–1751PubMed
272.
Kearon C, Comp P, Douketis J, Royds R, Yamada K, Gent M (2005) Dose–response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 3:962–968PubMed
273.
Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R et al (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5:31–41PubMed
274.
Levi M (2010) Japanese consensus for disseminated intravascular coagulation (DIC): is it a small world after all? Thromb Res 125:4–5PubMed
275.
Takagi T, Taguchi O, Toda M, Ruiz DB, Bernabe PG, D’Alessandro-Gabazza CN, et al (2011) Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med 183:31–42
Metadata
Title
Thrombomodulin and its role in inflammation
Author
Edward M. Conway
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 1/2012
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-011-0282-8

Other articles of this Issue 1/2012

Seminars in Immunopathology 1/2012 Go to the issue

Review

Coagulation and inflammation—close allies in health and disease

Review

Protease-activated receptor 2 signaling in inflammation

Review

Sphingosine 1-phosphate in coagulation and inflammation

Review

Protein C anticoagulant system—anti-inflammatory effects

Review

The roles of thrombin and protease-activated receptors in inflammation

Review

Endothelium—role in regulation of coagulation and inflammation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits